In a successful week for the medical technology companies in the LSI Alumni community, we saw over $100 million raised, regulatory approvals, new partnerships and much more on the road to LSI Europe '24 in Sintra, Portugal this September.
Parent company, 4D Medicine Ltd, raised a £3.4m investment deal led by Oshen Holdings. This financing was also backed by DSW Ventures, SFC Capital, Boundary Capital Partners LLP, and a number of private angel investors.
Announced a partnership with Medbionix, a leading medical technology distributor in Southern India. This collaboration will introduce ActivSight to hospitals throughout India to advance surgical precision and improving patient outcomes through its innovative visualization technology.
Announced that Eddie Gobran, Managing Partner of Leva Capital, has joined the Board of Directors. The company’s patented Pillar™ Technology improves anchoring consistency in the GI tract, minimizing procedure time and enabling more complete procedures on the first attempt.
Announced the company has acquired Wellen, a Brooklyn-based health technology company reinventing exercise-based osteoporosis care as a personalized and science-backed solution. The company’s first FDA-approved device, Osteoboost, is poised to become the new standard of care in treating postmenopausal osteopenia.
Brainomix
Announced new study data validating its AI technology across US stroke networks. The company specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis.
Received FDA 510(k) clearance and Announced the Appointment of Clément Vidal as new CEO. The eCential Robotics platform is an open surgical platform combining 2D/3D imaging, real-time navigation, and robotics for bone surgery, enabling a more efficient surgical workflow.
Received FDA clearance for the entire FibriCheck ecosystem. The FibriCheck mobile app is a medically certified detection and monitoring application that can be used to detect or monitor an irregular heart rhythm, such as atrial fibrillation.
Announced that Sutter Health is set to implement Flosonics' wireless, wearable Doppler ultrasound device, FloPatch, to enhance the safety of intensive care unit (ICU) patients. The company offers a fast, hands-free method for clinicians to assess blood flow, aiding in the management of cardiopulmonary resuscitation and fluid administration in critically ill patients.
Received FDA 510(k) clearance for its 7-F peripheral reperfusion system. The iCHOR Percutaneous Reperfusion System treats a wide range of arterial and venous occlusions and is currently in development of a pure solution for deep vein thrombosis.
Received CE Mark certification of full-body MRI compatibility for its Inspire IV neurostimulator device. The company is focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA).
Announced the commercial launch of the MyHand System, a post-stroke medical device system designed to aid hand function disability. This company's device is an in-clinic digital rehabilitation system, designed to rewire the brain through the power of neuroplasticity.
Closed a $105 million financing round led by Novo Holdings. New investors Viking Global Investors and RA Capital Management, and existing investors OrbiMed, New Enterprise Associates (NEA), JVC Investment Partners, and ALIVE - Israel HealthTech Fund, also participated in the round. The financing will be used to advance the company's U.S. clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first FDA approval for the Elevate™ System in patients undergoing high-risk percutaneous coronary interventions (HR-PCI).
Announced the successful completion of the first holographic cardiac ablation guided by SentiAR's CommandEP system. The company has developed the world’s first FDA-cleared, holographic, augmented reality (AR) platform designed to enhance the efficiency of cardiac ablation procedures.
Received FDA 510(k) clearance for its TMINI® Miniature Robotic System (TMINI 1.1). The company's TMINI 1.1 system software provides substantial new capabilities empowering surgeon choice throughout total knee arthroplasty procedures.
Announced the expansion of the AMEND™ TS EU Pilot Study to Italy. The company's technology is designed to transform mitral valve therapy through the development of advanced, minimally invasive solutions.
Entered into Joint Development Agreement with GE HealthCare to enhance arrhythmia procedures. This agreement aims to integrate the Volta AF-Xplorer™, with GE HealthCare’s latest digital platform, Prucka™ 3 and CardioLab™ EP Recording system. The combined solutions are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation (AFib).
Stay tuned for more updates, insights, and achievements of our LSI Alumni in our Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
